Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long(University of Sydney), Daniil Stroyakovskiy(Moscow City Oncology Hospital №62), Helen Gogas(National and Kapodistrian University of Athens), E. Levchenko(Institute of Oncology NN Petrov), Filippo de Braud(Fondazione IRCCS Istituto Nazionale dei Tumori), James Larkin(Royal Marsden Hospital), Claus Garbe(University of Tübingen), Thomas Jouary(Hôpital Saint-André), Axel Hauschild(University of Lübeck), Jean‐Jacques Grob(Aix-Marseille Université), Vanna Chiarion‐Sileni(Istituto Oncologico Veneto), Célèste Lebbé(Délégation Paris 7), Mario Mandalà(Ospedale Papa Giovanni XXIII), Michael Millward(Sir Charles Gairdner Hospital), Ana Arance(Hospital Clínic de Barcelona), Igor Bondarenko(Dnipropetrovsk State Medical Academy), John B.A.G. Haanen(The Netherlands Cancer Institute), Johan Hansson(Karolinska University Hospital), Jochen Utikal(German Cancer Research Center), Virginia Ferraresi(Fondazione IRCCS Istituto Nazionale dei Tumori), Н. В. Коваленко, Peter Mohr(Elbe Kliniken Stade-Buxtehude), Volodymr Probachai, Dirk Schadendorf(Essen University Hospital), Paul Nathan(Mount Vernon Cancer Centre), Caroline Robert(Bicêtre Hospital), Antoni Ribas(University of California, Los Angeles), Douglas J. DeMarini(Novartis (United States)), Jhangir G Irani(Novartis (United States)), S. Swann(Novartis (United States)), Jeffrey J. Legos(Novartis (United States)), Fan Jin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bijoyesh Mookerjee(Novartis (United States)), Keith T. Flaherty(Massachusetts General Hospital)
Cited by 1,381